Illumina (ILMN) Stock Forecast & Price Target

Illumina is supported by a strengthening clinical sequencing franchise, with durable mid-teens growth potential driven by oncology volume, improving reimbursement, and rising adoption of MRD, tumor profiling, and NGS-based blood tests. Its core economics remain attractive because sequencing consumables carry gross margins well above 70%, flow cells are around the 80s%, and instrument demand is being reinforced by strong NovaSeq X placements and healthy backlog. In addition, the new BioInsight business could add 1-2 points of growth from new products and create a longer-term biopharma data monetization opportunity, while management sees only manageable competitive pressure and can protect margins through pricing, scale, and a leading cost base.

Illumina is viewed negatively because its growth outlook is increasingly fragile: clinical growth, though recently 17%, is still being questioned for sustainability, while research and academic demand remain weak and pharma spending has not improved. Competitive intensity in nextgen sequencing is now described as the strongest in 15 years, with Roche, MGI, private rivals, and long-read companies pressuring share, pricing, and customer economics, including deflation in per-sample unit economics. China adds another layer of risk, as sales there are expected to fall to about 5% of 2026 revenue from 10% a few years ago, while the shift from NovaSeq 6000 to NovaSeq X pressures core revenue, margins, and gross margins.